|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash and Cash Equivalents, Period Increase (Decrease) | |||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||
| Provision for credit losses | |||||
| Depreciation | |||||
| Amortization of intangible assets | |||||
| Deferred income taxes | |||||
| Net (accretion) amortization of securities premiums and discounts | |||||
| Net realized loss on sales of securities | |||||
| Earnings and proceeds on life insurance policies | |||||
| Gain on sales of fixed assets and foreclosed real estate owned | |||||
| Net amortization of loan fees | |||||
| Net gain on sale of loans | |||||
| Mortgage loans originated for sale | |||||
| Proceeds from sale of loans originated for sale | |||||
| Compensation expense related to stock options | |||||
| Compensation expense related to restricted stock | |||||
| Increase in accrued interest receivable | |||||
| (Decrease) increase in accrued interest payable | |||||
| Other, net | |||||
| Net Cash Provided by Operating Activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||
| Securities available for sale: | |||||
| Proceeds from sales | |||||
| Proceeds from maturities and principal reductions on mortgage-backed securities | |||||
| Purchases | |||||
| Purchase of regulatory stock | |||||
| Redemption of regulatory stock | |||||
| Net increase in loans | |||||
| Proceeds from bank-owned life insurance | |||||
| Purchase of bank-owned life insurance | |||||
| Purchase of premises and equipment | |||||
| Proceeds from sales of foreclosed real estate owned | |||||
| Proceeds from sales of bank premises and fixed assets | |||||
| Net Cash Used for Investing Activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||
| Net increase in deposits | |||||
| Net (decrease) increase in short-term borrowings | |||||
| Repayments of other borrowings | |||||
| Proceeds from other borrowings | |||||
| Stock options exercised | |||||
| Sale of treasury stock for ESOP | |||||
| Acquisition of treasury stock | |||||
| Common stock Issuance | |||||
| Cash dividends paid | |||||
| Net Cash Provided by Financing Activities | |||||
| Net (Decrease) Increase in Cash and Cash Equivalents | |||||
| CASH AND CASH EQUIVALENTS - BEGINNING | |||||
| CASH AND CASH EQUIVALENTS - ENDING | |||||
| Supplemental Disclosures of Cash Flow Information | |||||
| Cash payments for: | |||||
| Interest paid | |||||
| Income taxes paid, net of refunds | |||||
| Supplemental Schedule of Noncash Investing Activities | |||||
| Transfers of loans to foreclosed real estate owned and repossession of other assets | |||||
| Dividends payable | |||||
| Impact of adopting ASC 326 | |||||
| Right of use for operating leases | |||||
| Lease liability for operating leases | |||||
Loading...